Abstract:Chemotherapy with Docetaxel (Doc) is efficient in a subset of prostate cancer (PCa) cases; however, most patients ultimately develop resistance to Docetaxel. The tumor immune microenvironment and secreted cytokines play a substantial role in development of resistance to chemotherapy. Our previous study has demonstrated that CD4+ T cells in prostate tumor microenvironment contribute to PCa progression; meanwhile, we found increased CD4+ T‐cell infiltration in tumor area after Doc treatment; however, their effects on PCa chemosensitivity remain unclear. Here, we aim to explore the role and mechanisms of CD4+ T cells in PCa chemotherapy sensitivity.CD4+ T‐cell infiltration in Doc‐treated paraffin‐embedded specimens from transurethral resection of prostate, radical prostatectomy, or bone metastasis was detected by immunohistochemistry. The castration‐resistant PCa cell lines—C4‐2 and CWR22RV1, and CD4+ T‐cell lines—HH and Molt‐3 were used in the coculture system. After coculture with the lymphocytes, PCa cell chemosensitivity was detected by cell counting kit‐8, terminal deoxynucleotidyl transferase dUTP nick‐end labeling assays, and Western blot analysis. Various cell cytokines were determined by cytokine arrays and reverse‐transcription polymerase chain reaction. The recombinant human C‐C motif chemokine ligand 5 (CCL5) was added to PCa cells for further confirming its effects and anti‐CCL5 antibody was used for neutralization. S3I‐201, a signal transducer and activator of transcription 3 (STAT3) inhibitor, was added to the coculture system to detect STAT3 role in chemosensitivity. Tumor xenografts in nude mice were used for confirming effects of CD4+ T cells in vivo study.We found more infiltrated CD4+ T cells in human PCa lesions than in the adjacent noncancerous tissues after Doc treatment. In vitro cell line study confirmed that CD4+ T cells increase the PCa Doc resistance. Quantative polymerase chain reaction and cytokine arrays indicated that after coculture with PCa, CD4+ T cells could secrete large amounts of CCL5. Moreover, CCL5 stimulation enhanced PCa resistance to Doc, and anti‐CCL5 antibody could partly reverse this process. We found that CD4+ T cells could activate P‐STAT3 signaling via secreting CCL5 and adding a STAT3 inhibitor can reverse the chemoresistance. In vivo mouse model with xenografted 22RV1 cells and CD4+ T cells also confirmed the in vitro results.Together, our results indicate that infiltrating CD4+ T cells could promote PCa chemotherapy resistance via modulation of the CCL5/STAT3 signaling pathway.

CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.

Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization

CCL2 Promotes EGFR-TKIs Resistance in Non-Small Cell Lung Cancer Via the AKT-EMT Pathway

SOX2 Regulates Paclitaxel Resistance of A549 Non‑small Cell Lung Cancer Cells Via Promoting Transcription of ClC‑3

CCL20 Triggered by Chemotherapy Hinders the Therapeutic Efficacy of Breast Cancer.

Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin

Epithelial-mesenchymal Transition Contributes to Docetaxel Resistance in Human Non-Small Cell Lung Cancer.

Long Noncoding RNA CCAT1 Acts As an Oncogene and Promotes Chemoresistance in Docetaxel-Resistant Lung Adenocarcinoma Cells.

Cathepsin L-mediated Resistance of Paclitaxel and Cisplatin is Mediated by Distinct Regulatory Mechanisms.

CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer

Inhibition of ZEB1 Reverses EMT and Chemoresistance in Docetaxel-Resistant Human Lung Adenocarcinoma Cell Line.

An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer

A Mirna-200C/cathepsin L Feedback Loop Determines Paclitaxel Resistance in Human Lung Cancer A549 Cells in Vitro Through Regulating Epithelial–mesenchymal Transition

Identification of ING 4 ( Inhibitor of Growth 4 ) as a Modulator of Docetaxel Sensitivity in Human Lung Adenocarcinoma

Transcriptome Profiling Analysis Reveals That CXCL2 is Involved in Anlotinib Resistance in Human Lung Cancer Cells

Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling

Epithelial - mesenchymal transition contributes to human non - small lung cancer cell line A549 docetaxel resistance

CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells.

Chemokine CCL20 Promotes the Paclitaxel Resistance of CD44+CD117+ Cells Via the Notch1 Signaling Pathway in Ovarian Cancer

Sox2 Inhibits Wnt-β-catenin Signaling and Metastatic Potency of Cisplatin-Resistant Lung Adenocarcinoma Cells